London, 29 September 2014 – TechNavio, a global tech-focused research firm has announced the publication of its market research report on the Global COPD Market 2014-2018.
About Chronic Obstructive Pulmonary Disease
COPD covers various progressive lung diseases including emphysema, chronic bronchitis, refractory (non-reversible) asthma and some forms of bronchiectasis. It is a serious condition that restricts airflow in the lungs, leading to increasing breathlessness. The Global COPD market is expected to witness an improvement in its growth rate and post a CAGR of 5.69 percent during the forecast period.
About the Report
The latest report by TechNavio focuses on the number of patients suffering from COPD that is growing rapidly due to aging populations, both in developing and developed countries. The report also discusses an increasing awareness of COPD among patients and physicians, which is expected to contribute to overall market growth.
“Enhanced patient and physician awareness of COPD is expected to lead to earlier disease diagnosis and treatment. The acceptance of COPD drugs will also grow because of this public awareness. This will probably result in an increase in drug penetration and will also contribute to the growth of the market,” says Faisal Ghaus, Vice President of TechNavio.
Key Information Covered in the Report:
Market segmentation, size and forecast through 2018
Market Growth Drivers:
- Increase in Aging Population
- For a full detailed list, view our report.
Market Challenges:
- High Cost
- For a full detailed list, view our report.
Market Trends:
- Increase in Awareness of COPD
- For a full detailed list, view our report.
Key Vendors:
- AstraZeneca plc
- Boehringer Ingelheim GmbH
- GlaxoSmithKline plc
- Novartis AG
- Pfizer Inc.
Other Prominent Vendors:
- Axis-Shield
- Beckton Dickinson
- Dainippon Sumitomo Pharma
- Medtronic
https://www.technavio.com/%3Cp%3E%3Ca%20href%3D%22http%3A//www.technavio….
